Amneal's generic Tamiflu now available in USA

9 August 2017
drugs_pills_tablets_big

Privately-held USA-headquartered generics manufacturer Amneal Pharmaceuticals has launched infuenza drug oseltamivir phosphate capsules, USP in three strengths:  30mg, 45mg and 75mg, in the USA.

The Amneal generic is an AB-rated therapeutic equivalent to Tamiflu, which was developed and is marketed by Swiss pharma giant Roche (ROG: SIX).  Each strength is available in 10-count blister dose-packs.

“Flu season is closer than we realize,” says Jim Luce, Amneal executive vice president, sales and marketing at Amneal, adding: “Amneal strives to assist healthcare providers and their patients by providing access to affordable treatments with our generic medication.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics